Introduction
Recombinant DNA technology has revolutionized the study of human inherited disease. Initially, the impact was felt in the elucidation of the molecular bases for defects in known genes such as mutations in the globin genes causing thalassemia. More recently, the realization that molecular techniques could be used to directly detect DNA sequence variation in human populations has fostered a general approach to the investigation of the great majority of genetic diseases in which the biochemical deficit is not known (1, 2) .
Restriction fragment-length polymorphism (RFLP)'
Until recently, detection of DNA sequence differences at specific human loci was necessarily indirect, and limited to those causing altered expression of a protein. Only a relatively small number of plasma and red cell proteins displayed sufficient electrophoretic or antigenic variation to be generally useful to genetic investigators. Now, with the availability of molecular techniques, sequence differences in the DNA of two chromosomes can be directly monitored in several ways which do not require that they affect expressed sequences. By far the easiest and most commonly employed approach is to cut genomic DNA with a restriction endonuclease, fractionate the digest by gel electrophoresis, transfer the DNA to a solid filter support, and hybridize with a cloned DNA probe for the region in question to determine the sizes of fragments produced from the corresponding locus. A given restriction endonuclease will only cleave DNA at particular recognition sites where a specific sequence ofbases occurs. Any alteration in the primary sequence of the DNA at one of these sites will eliminate cutting by the enzyme and will consequently change the size of the restriction fragment produced (see Fig. 1 ). Inherited differences in the pattern of enzyme digestion have been termed restriction fragment-length polymorphisms (2) . These can also result, of course, from more complex differences than single base changes, such as insertion or deletion of DNA within a restriction fragment. They can be found either at known gene loci, or using anonymous DNA sequences of no known function.
The value of an RFLP, like any other genetic marker, is that it permits the investigator to distinguish the two homologous chromosomes in an individual heterozygous at the polymorphic site. The geneticist is therefore able to infer from the alleles present in children which parental chromosome was transmitted in each case. If the RFLP is at a defective locus known to be present in an individual, it enables inferences to be made concerning the inheritance of the gene defect in the family. The practical application of RFLPs for known disease loci, particularly in prenatal diagnosis, is straightforward and has been used with many cloned genes responsible for specific inherited defects such as thalassemia, sickle cell anemia, growth hormone deficiency, and phenylketonuria (3) (4) (5) (6) .
In inherited diseases where the functional deficit is unknown, the availability of RFLPs as genetic markers has opened the door to genetic linkage investigations aimed at determining the chromosomal positions of the disease loci (1, 2). The basis for such studies is the fact that two genes located close to one another on the same chromosome will be transmitted together with a frequency far greater than chance alone would predict. In fact, alleles at such sites will only be transmitted separately when a recombination event occurs between the two loci. The chances for such a crossover increase with the distance between the genes. The degree of co-inheritance of two genes can therefore be used as a measure of their proximity on the chromosome. Similarly, if a disease and a genetic marker show a correlated pattern of inheritance, it implies that the disease gene is in the same chromosome region as the marker locus.
The search for RFLPs
In 1980, when human geneticists were first considering the use of RFLPs as genetic markers, there were three fundamental questions, the answers to which would determine the future of this approach. Could Fig. 2 suggests that many more DNA markers will be found in the next few years. Underlying this rapid accumulation is the high degree of sequence heterozygosity in the human genome. Several investigations have indicated that on average I base in 250 to 500 differs between any two chromosomes chosen at random (8-1 1). Thus, for any given probe, a screen using multiple restriction enzymes has a very high probability of identifying at least one RFLP. Predictably, larger probes are more likely to detect polymorphisms than shorter segments (12) .
Most RFLPs have been found by simply comparing the pattern of fragments detected by a cloned probe in restriction enzyme-digested DNA from a relatively small number of unrelated individuals (13) . Differences in pattern with a given enzyme can often be interpreted directly as the gain or loss of a restriction enzyme site. If similar differences are seen with many enzymes, an insertion or deletion is usually the basis for the polymorphism (14) . To The vast majority ofindividual RFLPs described involve the presence or absence of a restriction enzyme site and therefore have two alleles (7) . The use ofa small set ofunrelated individuals in the original screen for RFLPs favors the detection of polymorphisms with a high level of heterozygosity (13) . The frequency of the less common allele for most RFLP markers falls in the range of 0.15-0.5, which corresponds to levels of heterozygosity of 25-50%. This compares very favorably with most of the standard expressed markers. Two allele systems are naturally limited in informativeness, however, since at least 50% of the individuals will be homozygous at the locus, and it will be impossible to distinguish transmission of the two homologs.
The polymorphism information content or PIC value is a parameter that can be used to express the usefulness of a particular marker system (2) . It is the likelihood that a child of an arbitrary mating will yield information concerning transmission of the locus in question. PIC is a function of the number of alleles at a locus and oftheir individual frequencies in the general population. A fully informative marker would have a PIC of one. The maximum PIC for a two-allele system is 0.37, which indicates that on average only one mating in three will be informative. Few of the standard expressed markers exceed a PIC of 0.37. Fortunately, a major advantage of DNA markers is the ability to combine into haplotypes the individual alleles at RFLPs closely spaced in the genomic DNA, and thereby generate multiallele systems with greater informativeness (Fig. 1) . For most markers ofthis kind, it is necessary to digest DNA using multiple different restriction enzymes to monitor each ofseveral different two-allele systems.
The most useful DNA markers are those that detect multiallele systems due to length variation of the DNA within a particular fragment. Unfortunately, these markers are less frequent than single site variations. It has recently been determined, however, that the basis for this length variation is likely to be a high frequency of unequal crossovers within a set of short direct repeats (16) . RFLPs of the insertion/deletion type have been described near the insulin, Harvey ras, alpha globin, and myoglobin genes as well as with several anonymous probes (7) . At least one of these repeat units shows partial homology with the chi recombination signal of Escherichia coli ( 16) . It is likely that a systematic search for similar loci using these repeats as probes will yield many more multiallele markers.
As indicated in Fig. 2 (19) . It is possible that the improvement and extension of multipoint methods of analysis combined with a detailed human linkage map will eventually permit a linkage approach to diseases involving multifactorial inheritance, including complex behavioral disorders.
Diseases mapped by linkage to RFLPs
The use of RFLPs as genetic linkage markers has already resulted in the successful localization of a number of disease loci. The approach has been most intensively pursued on the X-chromosome. The first X-linked disease for which a linked RFLP was identified was Duchenne muscular dystrophy in 1982 (20) . A concentrated effort on the Duchenne muscular dystrophy region has now produced a large number of linked genetic markers and has brought investigators to the very brink of identifying the gene defect itself (21) (22) (23) . The ease of analysis of sex-linked disorders, due to the presence of a single allele at each locus in males, has allowed the detection of linked markers for Alport syndrome, Becker muscular dystrophy, X-linked Charcot-MarieTooth disease, choroideremia, Fragile X mental retardation syndrome, Menkes disease, ocular albinism, X-linked retinitis pigmentosa, and retinoschisis (24) . In fact, given the 68 polymorphic DNA markers that have been generated for this chromosome, it is virtually guaranteed that a linkage can be found for any X-linked disorder with an adequate number of reasonable-sized pedigrees.
The first major success in the application of the RFLP approach to autosomes came with the discovery in 1983 ofa marker tightly linked to Huntington's disease (HD) (25, 26) . As a result, the defect has now been assigned to the terminal region of the chromosome 4 short arm (27) . More recently, it has been reported that the alpha globin locus is genetically linked to the defect causing polycystic kidney disease (28) . A In addition to aiding in disease categorization, the linked marker can be used to explore the relationship of any of a large number of biochemical, physical, and behavioral parameters to the presence ofthe primary defect and to assess their involvement in the disease process. Perhaps the greatest impact of the chromosomal localization of a disease gene, however, is the avenue it opens toward cloning and characterizing the defective gene sequence without resort to a knowledge of the encoded protein.
A number of novel techniques are currently being developed to aid in implementing this "reverse genetics" approach which may ultimately result in the isolation of many ofthe more important human disease genes (26) . The identification ofdefective proteins through cloning of the coresponding gene sequences will undoubtedly improve our understanding of the biochemical bases for many disease phenotypes and may, in some cases, suggest effective forms of therapy.
